ARTICLE SUMMARY:
About five years after its first successful demonstration of a fully automated fluid management system, Reprieve Cardiovascular is preparing a pivotal trial of its Reprieve System for personalized decongestion, diuretic dosing, and fluid management in patients with acute decompensated heart failure.
Massachusetts company Reprieve Cardiovascular was founded in 2018 to advance technology originally developed by RenalGuard Solutions, a company focused on protecting the kidneys from contrast agents used for imaging during cardiac interventions. In late 2019, Reprieve demonstrated a personalized volume management system could safely reduce fluid volume in patients with acute decompensated heart failure (ADHF). (See “Reprieve Cardiovascular: Improving the Front-Line Therapy for Acute Decompensated HF,” MedTech Strategist, April 3, 2019.)
